FTII: FutureTech II Acquisition Corp. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 60.48
Enterprise Value ($M) 63.93
Book Value ($M) -7.76
Book Value / Share -1.46
Price / Book -7.79
NCAV ($M) -34.69
NCAV / Share -6.54
Price / NCAV -1.74

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) 0.01
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.25
Current Ratio 0.25

Balance Sheet (mrq) ($M)
Current Assets 1.56
Assets 28.50
Liabilities 36.26
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-12 13G/A Calamos Investment Trust/il
02-06 13G/A Walleye Capital LLC
11-14 13G/A Polar Asset Management Partners Inc. 0.00 -100.00
11-13 13G/A Aqr Capital Management Llc 0.00 -100.00
11-13 13G/A Cowen And Company, Llc 4.10 -67.65
11-08 13G Hudson Bay Capital Management LP 6.77
06-07 13G/A Karpus Management, Inc. 2.34 -82.72
03-01 13G/A Wolverine Asset Management Llc 4.44 -78.07
2024-02-22 13G/A Shaolin Capital Management LLC 0.00
2024-02-13 13G/A Atw Spac Management Llc 0.00 -100.00

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-04-05 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)

Similar Companies
FBRX – Forte Biosciences, Inc. FENC – Fennec Pharmaceuticals Inc.
FLGC – Flora Growth Corp. FTLF – FitLife Brands, Inc.
GALT – Galectin Therapeutics Inc.


Financial data and stock pages provided by
Fintel.io



This entry was posted in . Bookmark the permalink.